The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Regulation of C-Terminal and Intact FGF-23 by Dietary Phosphate in Men and Women
Open accessAbstract
FGF-23 is a novel regulator of phosphate metabolism. We studied the regulation of FGF-23 by dietary phosphate in 66 men and women using two assays. Dietary phosphate restriction decreased FGF-23 and loading increased FGF-23 significantly. An assay that measured intact FGF-23 showed the effects of dietary phosphate much more clearly than an assay that also measures presumed biologically inactive fragments. Dietary phosphate is a key regulator of circulating FGF-23; choice of assay is critical when studying FGF-23 physiology. Introduction: Fibroblast growth factor 23 (FGF-23) is a novel phosphaturic factor discovered through genetic studies of patients with renal phosphate wasting disorders. Ablation of the FGF-23 gene in mice reduces renal phosphate excretion and increases serum phosphate, suggesting that FGF-23 is critical for normal phosphate homeostasis. We examined the role of dietary phosphate in the regulation of FGF-23 in humans. Materials and Methods: Sixty-six healthy males and females were randomized to either phosphate-depleted or -loaded diets for 5 days, after a 4-day run-in diet. FGF-23 was measured using an “intact” assay that only detects intact FGF-23 peptide and with a “C-terminal” assay that measures both intact FGF-23 peptide and presumed biologically inactive carboxyl terminal fragments. The main outcome was the within group change in FGF-23 with either phosphate depletion or loading. Results: Using the intact FGF-23 assay, mean FGF-23 area under the curve (AUC) decreased by 9 ± 16% with phosphate depletion (p = 0.0041) and increased by 35 ± 29% with loading (p < 0.0001). Using the C-terminal FGF-23 assay, mean FGF-23 AUC decreased by 8 ± 12% with phosphate depletion (p = 0.0003) and increased by 13 ± 20% with loading (p = 0.0016). Increases in FGF-23 with phosphate loading were greater with the intact assay than with the C-terminal assay (p = 0.0003). Using the intact assay only, FGF-23 was significantly associated with serum phosphate (r = 0.39, p < 0.01), 24-h urinary phosphate (r = 0.47, p < 0.01), fractional excretion of phosphate (r = 0.29, p < 0.01), and 1,25-dihydroxyvitamin D (r = −0.30, p < 0.01). The association between the assays was weak (r = 0.26, p < 0.01). Conclusions: Dietary phosphate is a key regulator of circulating FGF-23 levels in humans. Additionally, choice of assay is critical when performing physiologic investigations of FGF-23.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FGF-23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis
Shimada, T., Hasegawa, H., Yamazaki, Y., Muto, T., Hino, R., Takeuchi, Y., Fujita, T., Nakahara, K., Fukumoto, S., & Yamashita, T. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301264 · Cited by 1,883
Shimada, T., Kakitani, M., Yamazaki, Y., Hasegawa, H., Takeuchi, Y., Fujita, T., Fukumoto, S., Tomizuka, K., & Yamashita, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19081 · Cited by 1,596
Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23
White, K. E., Evans, W. E., O'Riordan, J. L. H., Speer, M. C., Econs, M. J., Lorenz-Depiereux, B., Grabowski, M., Meitinger, T., & Strom, T. M. (2000) · Nature Genetics · doi:10.1038/81664 · Cited by 1,528
Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia
Shimada, T., Mizutani, S., Muto, T., Yoneya, T., Hino, R., Takeda, S., Takeuchi, Y., Fujita, T., Fukumoto, S., & Yamashita, T. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.101545198 · Cited by 1,457
Hypovitaminosis D in Medical Inpatients
Thomas, M. K., Lloyd-Jones, D. M., Thadhani, R. I., Shaw, A. C., Deraska, D. J., Kitch, B. T., Vamvakas, E. C., Dick, I. M., Prince, R. L., & Finkelstein, J. S. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803193381201 · Cited by 1,423
Self-citationFibroblast Growth Factor 23 in Oncogenic Osteomalacia and X-Linked Hypophosphatemia
Jonsson, K. B., Zahradnik, R., Larsson, T., White, K. E., Sugimoto, T., Imanishi, Y., Yamamoto, T., Hampson, G., Koshiyama, H., Ljunggren, Ö., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020881 · Cited by 914
Self-citationLarsson, T., Nisbeth, U. L. F., Ljunggren, Ö., Jüppner, H., & Jonsson, K. B. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00328.x · Cited by 689
Self-citationYamazaki, Y., Okazaki, R., Shibata, M., Hasegawa, Y., Satoh, K., Tajima, T., Takeuchi, Y., Fujita, T., Nakahara, K., Yamashita, T., et al. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021105 · Cited by 671
Sitara, D., Razzaque, M. S., Hesse, M., Yoganathan, S., Taguchi, T., Erben, R. G., J+APw-ppner, H., & Lanske, B. (2004) · Matrix Biology · doi:10.1016/j.matbio.2004.09.007 · Cited by 542
Ferrari, S. L., Bonjour, J.-P., & Rizzoli, R. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1039 · Cited by 518
Slatopolsky, E., Finch, J., Denda, M., Ritter, C., Zhong, M., Dusso, A., MacDonald, P. N., & Brown, A. J. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118701 · Cited by 511
An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia
Benet-Pagès, A., Orlik, P., Strom, T. M., & Lorenz-Depiereux, B. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi034 · Cited by 507
Larsson, T., Marsell, R., Schipani, E., Ohlsson, C., Ljunggren, Ö., Tenenhouse, H. S., Jüppner, H., & Jonsson, K. B. (2004) · Endocrinology · doi:10.1210/en.2003-1768 · Cited by 499
Self-citationCirculating FGF-23 Is Regulated by 1α,25-Dihydroxyvitamin D3 and Phosphorus in Vivo
Saito, H., Maeda, A., Ohtomo, S.-I., Hirata, M., Kusano, K., Kato, S., Ogata, E., Segawa, H., Miyamoto, K.-I., & Fukushima, N. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m408903200 · Cited by 471
Shimada, T. (2002) · Endocrinology · doi:10.1210/en.143.8.3179 · Cited by 446
Shimada, T., Urakawa, I., Yamazaki, Y., Hasegawa, H., Hino, R., Yoneya, T., Takeuchi, Y., Fujita, T., Fukumoto, S., & Yamashita, T. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.12.102 · Cited by 429
Perwad, F., Azam, N., Zhang, M. Y. H., Yamashita, T., Tenenhouse, H. S., & Portale, A. A. (2005) · Endocrinology · doi:10.1210/en.2005-0777 · Cited by 425
Saito, H., Kusano, K., Kinosaki, M., Ito, H., Hirata, M., Segawa, H., Miyamoto, K.-I., & Fukushima, N. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207872200 · Cited by 414
Riggs, B. L., & Parfitt, A. M. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.041114 · Cited by 380
MEPE, a New Gene Expressed in Bone Marrow and Tumors Causing Osteomalacia
Rowe, P. S. N., de Zoysa, P. A., Dong, R., Wang, H. R., White, K. E., Econs, M. J., & Oudet, C. L. (2000) · Genomics · doi:10.1006/geno.2000.6235 · Cited by 363
Serum FGF23 Levels in Normal and Disordered Phosphorus Homeostasis
Weber, T. J., Liu, S., Indridason, O. S., & Quarles, L. D. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.7.1227 · Cited by 354
Econs, M. J. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.2.674 · Cited by 305
Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent
Berndt, T., Craig, T. A., Bowe, A. E., Vassiliadis, J., Reczek, D., Finnegan, R., Jan De Beur, S. M., Schiavi, S. C., & Kumar, R. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18563 · Cited by 293
MEPE has the properties of an osteoblastic phosphatonin and minhibin
Rowe, P. S. N., Kumagai, Y., Gutierrez, G., Garrett, I. R., Blacher, R., Rosen, D., Cundy, J., Navvab, S., Chen, D., Drezner, M. K., et al. (2004) · Bone · doi:10.1016/j.bone.2003.10.005 · Cited by 268
Parathyroid hormone activation of the 25-hydroxyvitamin D 3 -1α-hydroxylase gene promoter
Brenza, H. L., Kimmel-Jehan, C., Jehan, F., Shinki, T., Wakino, S., Anazawa, H., Suda, T., & DeLuca, H. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.4.1387 · Cited by 259
A Novel Recessive Mutation in Fibroblast Growth Factor-23 Causes Familial Tumoral Calcinosis
Larsson, T., Yu, X., Davis, S. I., Draman, M. S., Mooney, S. D., Cullen, M. J., & White, K. E. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2238 · Cited by 223
A Novel Mutation in Fibroblast Growth Factor 23 Gene as a Cause of Tumoral Calcinosis
Araya, K., Fukumoto, S., Backenroth, R., Takeuchi, Y., Nakayama, K., Ito, N., Yoshii, N., Yamazaki, Y., Yamashita, T., Silver, J., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0301 · Cited by 222
Tumors Associated With Oncogenic Osteomalacia Express Genes Important in Bone and Mineral Metabolism
De Beur, S. M. J., Finnegan, R. B., Vassiliadis, J., Cook, B., Barberio, D., Estes, S., Manavalan, P., Petroziello, J., Madden, S. L., Cho, J. Y., et al. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.6.1102 · Cited by 212
Levi, M., Lotscher, M., Sorribas, V., Custer, M., Arar, M., Kaissling, B., Murer, H., & Biber, J. (1994) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1994.267.5.f900 · Cited by 194
DOMINGUEZ, J. H., GRAY, R. W., & LEMANN, J. (1976) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-43-5-1056 · Cited by 191
FGF-23 Is Elevated by Chronic Hyperphosphatemia
Gupta, A., Winer, K., Econs, M. J., Marx, S. J., & Collins, M. T. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0724 · Cited by 168
Relation of plasma phosphate concentration to renal tubular reabsorption of phosphate.
Bijvoet, O. L. (1969) · PubMed · Cited by 156
Segawa, H., Kawakami, E., Kaneko, I., Kuwahata, M., Ito, M., Kusano, K., Saitô, H., Fukushima, N., & Miyamoto, K. (2003) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-003-1084-1 · Cited by 142
Chefetz, I., Heller, R., Galli-Tsinopoulou, A., Richard, G., Wollnik, B., Indelman, M., Koerber, F., Topaz, O., Bergman, R., Sprecher, E., et al. (2005) · Human Genetics · doi:10.1007/s00439-005-0026-8 · Cited by 122
Bresler, D., Bruder, J., Mohnike, K. L., Fraser, W. D., & Rowe, P. S. (2004) · Journal of Endocrinology · doi:10.1677/joe.1.05989 · Cited by 114
Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism
Kobayashi, K., Imanishi, Y., Miyauchi, A., Onoda, N., Kawata, T., Tahara, H., Goto, H., Miki, T., Ishimura, E., Sugimoto, T., et al. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.02053 · Cited by 103
Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism
Yamashita, H., Yamashita, T., Miyamoto, M., Shigematsu, T., Kazama, J. J., Shimada, T., Yamazaki, Y., Fukumoto, S., Fukagaw, M., & Noguchi, S. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1510055 · Cited by 85
Comparison of two assays for fibroblast growth factor (FGF)-23
Ito, N., Fukumoto, S., Takeuchi, Y., Yasuda, T., Hasegawa, Y., Takemoto, F., Tajima, T., Dobashi, K., Yamazaki, Y., Yamashita, T., et al. (2005) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-005-0625-4 · Cited by 82
Tebben, P. J., Singh, R. J., Clarke, B. L., & Kumar, R. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.12.1508 · Cited by 53
NPT2a — The Key to Phosphate Homeostasis
Kronenberg, H. M. (2002) · New England Journal of Medicine · doi:10.1056/nejme020098 · Cited by 50
REGULATION OF CALCIUM AND PHOSPHATE HOMEOSTASIS
Costanzo, L. S. (1998) · AJP Advances in Physiology Education · doi:10.1152/advances.1998.275.6.s206 · Cited by 34
Postmenopausal Bilateral Oophorectomy Is Not Associated With Increased Fracture Risk in Older Women
Antoniucci, D. M., Sellmeyer, D. E., Cauley, J. A., Ensrud, K. E., Schneider, J. L., Vesco, K. K., Cummings, S. R., & Melton, L. J. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.041220 · Cited by 31
Evaluation of Theoretical Renal Phosphorus Threshold as an Index of Renal Phosphorus Handling
Stamp, T. C. B., & Stacey, T. E. (1970) · Clinical Science · doi:10.1042/cs0390505 · Cited by 25
Cited by
Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis
Gutiérrez, O. M., Mannstadt, M., Isakova, T., Rauh-Hain, J. A., Tamez, H., Shah, A., Smith, K., Lee, H., Thadhani, R., Jüppner, H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706130 · Cited by 1,727
Self-citationThe Osteocyte: An Endocrine Cell … and More
Dallas, S. L., Prideaux, M., & Bonewald, L. F. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1026 · Cited by 1,042
Regulation of Phosphate Homeostasis by PTH, Vitamin D, and FGF23
Bergwitz, C., & Jüppner, H. (2010) · Annual Review of Medicine · doi:10.1146/annurev.med.051308.111339 · Cited by 741
Self-citationRegulation and Function of the FGF23/Klotho Endocrine Pathways
Martin, A., David, V., & Quarles, L. D. (2012) · Physiological Reviews · doi:10.1152/physrev.00002.2011 · Cited by 594
Hu, M. C., Shiizaki, K., Kuro-o, M., & Moe, O. W. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183727 · Cited by 587
Metadata
- Authors
- Burnett, S.-A. M., Gunawardene, S. C., Bringhurst, F. R., Jüppner, H., Lee, H., & Finkelstein, J. S.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-08-01
- Volume
- 21
- Issue
- 8
- Pages
- 1187-1196
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2059022155
- Cited by
- 455
- References
- 43
- FWCI
- 11.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.